drug · small molecule

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

updated 2mo ago

by $IGC IGC Pharma, Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for opioid dependence and drug dependence and 1 investigational indication.

targets

Kappa-type opioid receptorMu-type opioid receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

trade names

Belbuca, Buprenex, Buprenorphine hydrochloride, Buprenorphine hydrochloride component of bunavail, Buprenorphine hydrochloride component of cassipa, Buprenorphine hydrochloride component of suboxone

generic

BUPRENORPHINE HYDROCHLORIDE

MOA

12.1 Mechanism of Action Buprenorphine and naloxone sublingual tablets contain buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.

indication

1 INDICATIONS AND USAGE Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. Buprenorphine and naloxone sublingual tablets contain buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and are indicated for the maintenance treatment of opioid dependence. ( 1 ) Buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside